Last updated: May 17, 2016
|CMS Measure ID:||CMS73v3|
This measure assesses the number of patients diagnosed with confirmed VTE who received an overlap of parenteral (intravenous [IV] or subcutaneous [subcu]) anticoagulation and warfarin therapy. For patients who received less than five days of overlap therapy, they should be discharged on both medications or have a reason for discontinuation of overlap therapy. Overlap therapy should be administered for at least five days with an international normalized ratio (INR) greater than or equal to 2 prior to discontinuation of the parenteral anticoagulation therapy, discharged on both medications or have a reason for discontinuation of overlap therapy.
|Initial Patient Population:||
Patients with a diagnosis code for venous thromboembolism (VTE), a patient age greater than or equal to 18 years, and a length of stay less than or equal to 120 days.
Patients with confirmed VTE who received warfarin.
Patients who received overlap therapy (warfarin and parenteral anticoagulation):
|Measure Steward:||The Joint Commission|
|Domain:||Effective Clinical Care|
|Next Version:||Venous Thromboembolism Patients with Anticoagulation Overlap Therapy|
An increase in the rate
The unit of measurement for this measure is an inpatient episode of care. Each distinct hospitalization should be reported, regardless of whether the same patient is admitted for inpatient care more than once during the measurement period. In addition, the eMeasure logic intends to represent events within or surrounding a single occurrence of an inpatient hospitalization.
For date difference calculations, use the LAST (most recent) of the alternative dates as the end date and the EARLIEST of the alternative dates as the start date. The calculation should be performed as end date minus start date.